1. Home
  2. KURA vs HOV Comparison

KURA vs HOV Comparison

Compare KURA & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • HOV
  • Stock Information
  • Founded
  • KURA 2014
  • HOV 1959
  • Country
  • KURA United States
  • HOV United States
  • Employees
  • KURA N/A
  • HOV N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • HOV Homebuilding
  • Sector
  • KURA Health Care
  • HOV Consumer Discretionary
  • Exchange
  • KURA Nasdaq
  • HOV Nasdaq
  • Market Cap
  • KURA 793.2M
  • HOV N/A
  • IPO Year
  • KURA N/A
  • HOV N/A
  • Fundamental
  • Price
  • KURA $7.26
  • HOV $132.96
  • Analyst Decision
  • KURA Strong Buy
  • HOV Hold
  • Analyst Count
  • KURA 11
  • HOV 2
  • Target Price
  • KURA $27.89
  • HOV $155.00
  • AVG Volume (30 Days)
  • KURA 1.8M
  • HOV 94.6K
  • Earning Date
  • KURA 02-25-2025
  • HOV 02-20-2025
  • Dividend Yield
  • KURA N/A
  • HOV N/A
  • EPS Growth
  • KURA N/A
  • HOV 18.27
  • EPS
  • KURA N/A
  • HOV 31.79
  • Revenue
  • KURA N/A
  • HOV $3,004,918,000.00
  • Revenue This Year
  • KURA N/A
  • HOV $13.98
  • Revenue Next Year
  • KURA $233.30
  • HOV $8.26
  • P/E Ratio
  • KURA N/A
  • HOV $4.18
  • Revenue Growth
  • KURA N/A
  • HOV 9.03
  • 52 Week Low
  • KURA $6.98
  • HOV $115.90
  • 52 Week High
  • KURA $24.17
  • HOV $240.34
  • Technical
  • Relative Strength Index (RSI)
  • KURA 17.38
  • HOV 41.82
  • Support Level
  • KURA $6.98
  • HOV $115.90
  • Resistance Level
  • KURA $8.88
  • HOV $132.16
  • Average True Range (ATR)
  • KURA 0.33
  • HOV 5.27
  • MACD
  • KURA 0.05
  • HOV 0.82
  • Stochastic Oscillator
  • KURA 13.40
  • HOV 81.05

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Share on Social Networks: